Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer

(2017) Stephen J. Luen et al.   PATHOLOGY

Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group

(2016) Shannon K. Swisher et al.   ANNALS OF SURGICAL ONCOLOGY

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

(2016) Giancarlo Pruneri et al.   BREAST CANCER RESEARCH AND TREATMENT

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

(2016) Carsten Denkert et al.   MODERN PATHOLOGY

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method

(2015) A. I. Hida et al.   ANNALS OF ONCOLOGY

Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer

(2015) G. Pruneri et al.   ANNALS OF ONCOLOGY

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

(2015) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2014) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study

(2014) D. Balmativola et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

(2013) Yasmin Issa-Nummer et al.   PLoS One

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune infiltration in human tumors: a prognostic factor that should not be ignored

(2009) F Pagès et al.   ONCOGENE